Last updated: 6 March 2023 at 11:42am EST

Richard Aldrich Net Worth




The estimated Net Worth of Richard Aldrich is at least $5.1 Million dollars as of 6 June 2022. Mr. Aldrich owns over 210,526 units of Concert Pharmaceuticals Inc stock worth over $1,762,103 and over the last 13 years he sold CNCE stock worth over $3,181,163. In addition, he makes $157,592 as Independent Chairman of the Board and Co-Founder at Concert Pharmaceuticals Inc.

Mr. Aldrich CNCE stock SEC Form 4 insiders trading

Richard has made over 39 trades of the Concert Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 210,526 units of CNCE stock worth $999,999 on 6 June 2022.

The largest trade he's ever made was buying 766,667 units of Concert Pharmaceuticals Inc stock on 7 March 2013 worth over $11,500,005. On average, Richard trades about 31,655 units every 46 days since 2012. As of 6 June 2022 he still owns at least 210,526 units of Concert Pharmaceuticals Inc stock.

You can see the complete history of Mr. Aldrich stock trades at the bottom of the page.





Richard Aldrich biography

Richard H. Aldrich serves as Independent Chairman of the Board, Co-Founder of the Company. Mr. Aldrich is a co-founder of Concert and has served as a member of our Board and as Chairman of the Board since May 2006. Mr. Aldrich is a co-founder and was a Partner at Longwood Fund Management LLC, a venture capital firm, from December 2010 to December 2019. Mr. Aldrich has been an employee of Longwood Management LLC since August 2015. Mr. Aldrich founded RA Capital Management LLC, a hedge fund, in 2001 and served as a Managing Member from 2001 to 2008 and as a Co-Founding Member from 2008 to 2011. Mr. Aldrich has co-founded and helped to build several biotechnology companies including Sirtris Pharmaceuticals, Inc. (acquired by GlaxoSmithKline in 2008), Alnara Pharmaceuticals, Inc. (acquired by Eli Lilly in 2010), Verastem, Inc., OvaScience, Inc. and Flex Pharma, Inc. Mr. Aldrich was also a founding employee of Vertex Pharmaceuticals Incorporated, a pharmaceutical company, where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen Inc. Mr. Aldrich also serves on the board of directors of a number of private biotechnology companies. During the last five years, Mr. Aldrich previously served on the board of directors of PTC Therapeutics, Inc. and OvaScience, Inc. Mr. Aldrich received a B.S. in Management from Boston College and an M.B.A. from the Amos Tuck School at Dartmouth College.

What is the salary of Richard Aldrich?

As the Independent Chairman of the Board and Co-Founder of Concert Pharmaceuticals Inc, the total compensation of Richard Aldrich at Concert Pharmaceuticals Inc is $157,592. There are 7 executives at Concert Pharmaceuticals Inc getting paid more, with Roger Tung having the highest compensation of $2,772,350.



What's Richard Aldrich's mailing address?

Richard's mailing address filed with the SEC is C/O CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON, MA, 02421.

Insiders trading at Concert Pharmaceuticals Inc

Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V..., and Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.



What does Concert Pharmaceuticals Inc do?

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.



What does Concert Pharmaceuticals Inc's logo look like?

Concert Pharmaceuticals Inc logo

Complete history of Mr. Aldrich stock trades at Concert Pharmaceuticals Inc, KalVista Pharmaceuticals Inc, PTC Therapeutics Inc, and Verastem Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
6 Jun 2022 Richard Aldrich
Director
Buy 210,526 $4.75 $999,999
6 Jun 2022
210,526
15 Nov 2018 Richard Aldrich
Director
Buy 50,000 $11.83 $591,500
15 Nov 2018
336,975
30 Jan 2018 Richard Aldrich
Director
Sale 11,946 $20.89 $249,552
30 Jan 2018
0
25 Jan 2018 Richard Aldrich
Director
Sale 18,054 $20.63 $372,454
25 Jan 2018
11,946
22 Jan 2018 Richard Aldrich
Director
Sale 30,000 $19.68 $590,400
22 Jan 2018
47,405
17 Jan 2018 Richard Aldrich
Director
Sale 30,000 $19.35 $580,500
17 Jan 2018
62,405
16 Jan 2018 Richard Aldrich
Director
Sale 31,236 $19.14 $597,857
16 Jan 2018
77,405
16 Dec 2015 Richard Aldrich
Director
Sale 20,000 $19.76 $395,200
16 Dec 2015
286,975
16 Dec 2015 Richard Aldrich
Director
Sale 20,000 $19.76 $395,200
16 Dec 2015
286,975
12 Oct 2017 Richard Aldrich
Director
Buy 565,065 $8.61 $4,865,210
12 Oct 2017
934,484
8 Jun 2015 Richard Aldrich
Director
Option 7,000 $10.85 $75,950
8 Jun 2015
7,000
7 Mar 2013 Richard Aldrich
Director
Buy 766,667 $15.00 $11,500,005
7 Mar 2013
300,000
20 May 2014 Richard Aldrich
Director
Buy 1,000 $8.37 $8,370
20 May 2014
408,142
11 Nov 2013 Richard Aldrich
Director
Buy 1,000 $10.93 $10,930
11 Nov 2013
20,000
4 Nov 2013 Richard Aldrich
Director
Buy 1,000 $10.51 $10,510
4 Nov 2013
19,000
28 Oct 2013 Richard Aldrich
Director
Buy 1,000 $11.26 $11,260
28 Oct 2013
18,000
21 Oct 2013 Richard Aldrich
Director
Buy 1,000 $12.57 $12,570
21 Oct 2013
17,000
14 Oct 2013 Richard Aldrich
Director
Buy 1,000 $10.56 $10,560
14 Oct 2013
16,000
7 Oct 2013 Richard Aldrich
Director
Buy 1,000 $11.53 $11,530
7 Oct 2013
15,000
30 Sep 2013 Richard Aldrich
Director
Buy 1,000 $12.55 $12,550
30 Sep 2013
14,000
23 Sep 2013 Richard Aldrich
Director
Buy 1,000 $13.17 $13,170
23 Sep 2013
13,000
16 Sep 2013 Richard Aldrich
Director
Buy 1,000 $13.81 $13,810
16 Sep 2013
12,000
9 Sep 2013 Richard Aldrich
Director
Buy 1,000 $14.04 $14,040
9 Sep 2013
11,000
3 Sep 2013 Richard Aldrich
Director
Buy 1,000 $14.07 $14,070
3 Sep 2013
10,000
26 Aug 2013 Richard Aldrich
Director
Buy 1,000 $14.21 $14,210
26 Aug 2013
9,000
19 Aug 2013 Richard Aldrich
Director
Buy 1,000 $13.45 $13,450
19 Aug 2013
8,000
12 Aug 2013 Richard Aldrich
Director
Buy 1,000 $14.75 $14,750
12 Aug 2013
7,000
5 Aug 2013 Richard Aldrich
Director
Buy 1,000 $15.25 $15,250
5 Aug 2013
6,000
29 Jul 2013 Richard Aldrich
Director
Buy 1,000 $15.15 $15,150
29 Jul 2013
5,000
24 Jul 2013 Richard Aldrich
Director
Buy 1,000 $16.39 $16,390
24 Jul 2013
4,000
15 Jul 2013 Richard Aldrich
Director
Buy 1,000 $17.19 $17,190
15 Jul 2013
3,000
8 Jul 2013 Richard Aldrich
Director
Buy 1,000 $14.69 $14,690
8 Jul 2013
2,000
1 Jul 2013 Richard Aldrich
Director
Buy 1,000 $14.11 $14,110
1 Jul 2013
1,000


Concert Pharmaceuticals Inc executives and stock owners

Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: